Efalizumab, marketed under the brand name Raptiva, is a humanized monoclonal antibody used for the treatment of psoriasis. It is a full-length IgG1 antibody developed through a murine anti-human CD11a mAb and is produced in a Chinese hamster ovary mammalian cell expression system. Efalizumab works by blocking the CD11a, which is the alpha-chain of LFA-1 (leukocyte function associate antigen; integrin family) expressed on the surface of T-lymphocytes. This action inhibits the ability of T cells to adhere, migrate, and be activated, thus reducing the inflammatory response in psoriasis.
214745-43-4
Post Buying Request-
-
Basic information
- Product Name: EFALIZUMABUM
- Synonyms: EFALIZUMABUM
- CAS NO:214745-43-4
- Molecular Formula:
- Molecular Weight: 0
- EINECS: N/A
- Product Categories: N/A
-
Chemical Properties
- Melting Point: N/A
- Boiling Point: N/A
- Flash Point: N/A
- Appearance: /
- Density: N/A
- Refractive Index: N/A
- Storage Temp.: N/A
- Solubility: N/A
- CAS DataBase Reference: EFALIZUMABUM(CAS DataBase Reference)
- NIST Chemistry Reference: EFALIZUMABUM(214745-43-4)
- EPA Substance Registry System: EFALIZUMABUM(214745-43-4)
-
Safety Data
- Hazard Codes: N/A
- Statements: N/A
- Safety Statements: N/A
- WGK Germany:
- RTECS:
- HazardClass: N/A
- PackingGroup: N/A
- Hazardous Substances Data: 214745-43-4(Hazardous Substances Data)
214745-43-4 Suppliers
Recommended suppliers
214745-43-4 Usage
Uses
Used in Pharmaceutical Industry:Efalizumab is used as a treatment for psoriasis, an autoimmune disease characterized by the rapid growth of skin cells. It functions as an antipsoriatic agent, acting as an immunomodulator monoclonal antibody that decreases the activation, migration, and adhesion of T-cells expressing CD4 or CD8 markers. By targeting the CD11a, efalizumab downregulates the expression of LFA-1 on lymphocytes, which helps in preventing contact dermatitis and increasing the survival rate of skin and heart transplants.
Additionally, efalizumab has been studied for its potential use in treating transplant rejections, as it can help in delaying the onset and decreasing the severity of arthritic conditions in collagen-induced arthritis models.
Efalizumab is administered as a once-weekly subcutaneous injection, dosed at 0.7 to 1 mg/kg/week. Although mild adverse events such as headache, pain, chills, nausea, and fever have been reported, these generally decrease after one or two doses. The overall rate of infections was only 3% higher than the placebo-arm, and no depletion of T-cells was noted.
Originator
XOMA (US)Check Digit Verification of cas no
The CAS Registry Mumber 214745-43-4 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 2,1,4,7,4 and 5 respectively; the second part has 2 digits, 4 and 3 respectively.Calculate Digit Verification of CAS Registry Number 214745-43:
(8*2)+(7*1)+(6*4)+(5*7)+(4*4)+(3*5)+(2*4)+(1*3)=124
124 % 10 = 4
So 214745-43-4 is a valid CAS Registry Number.
214745-43-4Upstream product
214745-43-4Downstream Products
Post a RFQ
1
What can I do for you?
Get Best Price
Get Best Price for 214745-43-4
EFALIZUMABUM
